<table>
<thead>
<tr>
<th></th>
<th>All–cause mortality</th>
<th>Stroke mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>p value</td>
</tr>
<tr>
<td>Age, yr, /increment of 10</td>
<td>1.918 (1.500–2.453)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex, men</td>
<td>0.712 (0.434–1.168)</td>
<td>0.176</td>
</tr>
<tr>
<td>LSA territory involvement</td>
<td>2.246 (1.339–3.768)</td>
<td>0.002</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.426 (0.803–2.534)</td>
<td>0.226</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.354 (0.835–2.196)</td>
<td>0.219</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>0.637 (0.275–1.473)</td>
<td>0.291</td>
</tr>
<tr>
<td>Coronary disease</td>
<td>1.066 (0.608–1.870)</td>
<td>0.823</td>
</tr>
<tr>
<td>Current smoker</td>
<td>0.445 (0.220–0.898)</td>
<td>0.024</td>
</tr>
<tr>
<td>Previous antplatelet</td>
<td>0.744 (0.441–1.255)</td>
<td>0.268</td>
</tr>
<tr>
<td>Previous anticoagulant</td>
<td>0.394 (0.096–1.609)</td>
<td>0.194</td>
</tr>
<tr>
<td>Previous statin</td>
<td>0.507 (0.242–0.961)</td>
<td>0.072</td>
</tr>
<tr>
<td>Previous BP lowering medication</td>
<td>1.264 (0.782–2.042)</td>
<td>0.339</td>
</tr>
<tr>
<td>Previous DM medication</td>
<td>0.898 (0.327–2.471)</td>
<td>0.835</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>0.732 (0.664–0.808)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>0.868 (0.864–0.929)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>White blood cells, /increment of 1000</td>
<td>1.093 (1.015–1.176)</td>
<td>0.018</td>
</tr>
<tr>
<td>Platelet</td>
<td>1.001 (0.999–1.004)</td>
<td>0.678</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>1.025 (1.018–1.032)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>hsCRP</td>
<td>1.011 (1.007–1.014)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Prothrombin time, INR</td>
<td>0.838 (0.313–2.248)</td>
<td>0.726</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>0.993 (0.987–1.000)</td>
<td>0.035</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1.004 (0.983–1.027)</td>
<td>0.690</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>0.998 (0.991–1.006)</td>
<td>0.638</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>1.006 (1.002–1.011)</td>
<td>0.008</td>
</tr>
<tr>
<td>Glycated hemoglobin</td>
<td>1.107 (0.945–1.297)</td>
<td>0.208</td>
</tr>
<tr>
<td>Initial NIHSS score</td>
<td>1.109 (1.075–1.145)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Superficial MCA territorial infarction volume, /increment of 1 cm³</td>
<td>1.009 (1.005–1.013)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Significant brain swelling</td>
<td>4.406 (2.307–8.415)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Significant MCA stenosis</td>
<td>1.711 (0.987–2.967)</td>
<td>0.056</td>
</tr>
<tr>
<td>Significant ICA stenosis</td>
<td>2.395 (1.429–4.015)</td>
<td>0.001</td>
</tr>
<tr>
<td>High-risk PCSE</td>
<td>1.513 (0.922–2.483)</td>
<td>0.101</td>
</tr>
</tbody>
</table>

**Stroke subtype**

|                                | All–cause mortality | Stroke mortality |
|                                | HR (95% CI)         | p value         |
| Large artery atherosclerosis   | 1.182 (0.562–2.484) | 0.659           | 4.757 (0.585–38.673) | 0.145 |
| Cardioembolism                 | 0.850 (0.401–1.800) | 0.671           | 3.166 (0.381–26.298) | 0.286 |
| Two or more causes             | 1.388 (0.660–2.914) | 0.388           | 3.192 (0.357–26.563) | 0.299 |
| Negative evaluation            | 1 (Ref)             |                 | 1 (Ref)             |     |

LSA, lenticulostriate artery; BP, blood pressure; DM, diabetes mellitus; hsCRP, high sensitivity C-reactive protein; INR, international normalized ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NIHSS, National Institute of Health Stroke Scale; MCA, middle cerebral artery; ICA, internal carotid artery; PCSE, potential cardiac source of embolism; HR, hazard ratios; CI, confidence interval.